SEC Company Response from Ovid Therapeutics Inc. (OVID) (CIK 0001636651) (OVID) — Nov 18, 2020
Ovid Therapeutics Inc. (OVID) (CIK 0001636651)
Date: Nov. 18, 2020 · CIK: 0001636651 · Accession: 0001193125-20-297059
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-250054
Letter
OVID THERAPEUTICS INC.
1460 Broadway, Suite 15044
New York, NY 10036
November 18, 2020
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C.
Attn: Ada Sarmento
Re: Ovid Therapeutics Inc.
Registration Statement on Form S-3 (File No. 333-250054)
Request for Acceleration of Effective Date
Ms. Sarmento:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-250054) (the “Registration Statement”) to become effective on November 20, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096, or in her absence, Owen Williams at (202) 842-7843.
[Signature page follows]
Very truly yours,
Ovid Therapeutics Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP OVID THERAPEUTICS INC. 1460 Broadway, Suite 15044 New York, NY 10036 November 18, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada Sarmento Re: Ovid Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-250054) Request for Acceleration of Effective Date Ms. Sarmento: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-250054) (the “Registration Statement”) to become effective on November 20, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable (the “Staff”). Once the Registration Statement has been declared effective, please orally confirm that event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096, or in her absence, Owen Williams at (202) 842-7843. [Signature page follows] Very truly yours, Ovid Therapeutics Inc. By: /s/ Thomas M. Perone Thomas M. Perone General Counsel and Chief Compliance Officer cc: Jeremy Levin, Ovid Therapeutics Inc. Timothy Daly, Ovid Therapeutics Inc. Jeffery Rona, Ovid Therapeutics Inc. Laura Berezin, Cooley LLP Jaime Chase, Cooley LLP Owen Williams, Cooley LLP